| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected and Quantified |
|---|
| Creation Date | 2006-05-22 15:12:01 UTC |
|---|
| Update Date | 2022-03-07 02:49:16 UTC |
|---|
| HMDB ID | HMDB0002656 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Prostaglandin A1 |
|---|
| Description | Prostaglandin A1 (PGA1, a prostaglandin characterized by a cyclopentenone structure) has a fundamental structure common to punaglandin and clavulone, the antitumor eicosanoids discovered in marine organisms such as corals. It is well established that PGA1, which exert potent antiviral activity in several DNA and RNA virus models, induce heat shock protein (hsp)70 syntheses through cycloheximide sensitive activation of heat shock transcription factor. Antitumor prostaglandins are actively incorporated through cell membrane and control gene expression. P53 (protein 53, is a transcription factor that regulates the cell cycle and functions as a tumor suppressor) independent expression of p21 (also known as cyclin-dependent kinase inhibitor 1A or CDKN1A, is a human gene on chromosome 6 (location 6p21.2), that encodes a cyclin-dependent kinase) and gadd 45 (growth arrest and DNA-damage-inducible, alpha 45, a major breast cancer (BRCA1) target is the DNA damage-responsive gene GADD45) activation of peroxisome proliferative activated receptor gamma (PPARgamma) are involved in antitumor mechanism of these prostaglandins. At the low concentration, these prostaglandins exhibit physiological or pathological activity such as osteoblast calcification, promotion of colon cancer cell proliferation. One of the mechanisms of anti-cancer activity of prostaglandins, has been believed to be that these prostaglandins might have p53 like effect in cells lacking p53. (PMID: 7988663 , 11104898 )Prostaglandins are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. |
|---|
| Structure | CCCCC[C@H](O)\C=C\[C@H]1C=CC(=O)[C@@H]1CCCCCCC(O)=O InChI=1S/C20H32O4/c1-2-3-6-9-17(21)14-12-16-13-15-19(22)18(16)10-7-4-5-8-11-20(23)24/h12-18,21H,2-11H2,1H3,(H,23,24)/b14-12+/t16-,17-,18+/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (13E)-(15S)-15-Hydroxy-9-oxoprosta-10,13-dienoate | ChEBI | | PGA1 | ChEBI | | (13E)-(15S)-15-Hydroxy-9-oxoprosta-10,13-dienoic acid | Generator | | (13E,15S)-15-Hydroxy-9-oxo-prosta-10,13-dien-1-Oate | HMDB | | (13E,15S)-15-Hydroxy-9-oxo-prosta-10,13-dien-1-Oic acid | HMDB | | 15-Hydroxy-9-oxoprosta-10,13-dienoate | HMDB | | 15-Hydroxy-9-oxoprosta-10,13-dienoic acid | HMDB | | 15a-Hydroxy-9-ketoprosta-10,13-dienoate | HMDB | | 15a-Hydroxy-9-ketoprosta-10,13-dienoic acid | HMDB | | 15a-Hydroxy-9-oxo-10,13E-prostadienoate | HMDB | | 15a-Hydroxy-9-oxo-10,13E-prostadienoic acid | HMDB | | 2-(3-Hydroxy-1-octenyl)-5-oxo-3- cyclopentene-1-heptanoate | HMDB | | 2-(3-Hydroxy-1-octenyl)-5-oxo-3- cyclopentene-1-heptanoic acid | HMDB | | 2-(3-Hydroxy-1-octenyl)-5-oxo-3-cyclopentene-1-heptanoate | HMDB | | 2-(3-Hydroxy-1-octenyl)-5-oxo-3-cyclopentene-1-heptanoic acid | HMDB | | Prostaglandin e1-217 | HMDB | | Prostaglandin a1, (13E,15R)-(+-)-isomer | MeSH, HMDB | | Prostaglandin a1, (13E,15R)-isomer | MeSH, HMDB | | Prostaglandin a1, (13E,15S)-(+-)-isomer | MeSH, HMDB | | Prostaglandin a1, (8beta,12alpha,13E,15S)-isomer | MeSH, HMDB | | Prostaglandin a1 | MeSH |
|
|---|
| Chemical Formula | C20H32O4 |
|---|
| Average Molecular Weight | 336.4657 |
|---|
| Monoisotopic Molecular Weight | 336.230059512 |
|---|
| IUPAC Name | 7-[(1R,2S)-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopent-3-en-1-yl]heptanoic acid |
|---|
| Traditional Name | prostaglandin A1 |
|---|
| CAS Registry Number | 14152-28-4 |
|---|
| SMILES | CCCCC[C@H](O)\C=C\[C@H]1C=CC(=O)[C@@H]1CCCCCCC(O)=O |
|---|
| InChI Identifier | InChI=1S/C20H32O4/c1-2-3-6-9-17(21)14-12-16-13-15-19(22)18(16)10-7-4-5-8-11-20(23)24/h12-18,21H,2-11H2,1H3,(H,23,24)/b14-12+/t16-,17-,18+/m0/s1 |
|---|
| InChI Key | BGKHCLZFGPIKKU-LDDQNKHRSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Fatty Acyls |
|---|
| Sub Class | Eicosanoids |
|---|
| Direct Parent | Prostaglandins and related compounds |
|---|
| Alternative Parents | |
|---|
| Substituents | - Prostaglandin skeleton
- Long-chain fatty acid
- Fatty alcohol
- Hydroxy fatty acid
- Ketone
- Cyclic ketone
- Secondary alcohol
- Monocarboxylic acid or derivatives
- Carboxylic acid
- Carboxylic acid derivative
- Hydrocarbon derivative
- Alcohol
- Organic oxide
- Organic oxygen compound
- Organooxygen compound
- Carbonyl group
- Aliphatic homomonocyclic compound
|
|---|
| Molecular Framework | Aliphatic homomonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 8.2 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 16.0771 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 0.9 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 40.0 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2797.3 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 287.9 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 197.5 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 181.1 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 433.9 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 701.5 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 540.4 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 117.7 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1590.7 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 524.5 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1550.0 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 486.1 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 428.2 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 291.7 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 313.3 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 8.4 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Prostaglandin A1,1TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1C=CC(=O)[C@@H]1CCCCCCC(=O)O)O[Si](C)(C)C | 2801.9 | Semi standard non polar | 33892256 | | Prostaglandin A1,1TMS,isomer #2 | CCCCC[C@H](O)/C=C/[C@H]1C=CC(=O)[C@@H]1CCCCCCC(=O)O[Si](C)(C)C | 2711.2 | Semi standard non polar | 33892256 | | Prostaglandin A1,1TMS,isomer #3 | CCCCC[C@H](O)/C=C/[C@H]1C=CC(O[Si](C)(C)C)=C1CCCCCCC(=O)O | 2866.4 | Semi standard non polar | 33892256 | | Prostaglandin A1,2TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1C=CC(=O)[C@@H]1CCCCCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 2788.2 | Semi standard non polar | 33892256 | | Prostaglandin A1,2TMS,isomer #2 | CCCCC[C@@H](/C=C/[C@H]1C=CC(O[Si](C)(C)C)=C1CCCCCCC(=O)O)O[Si](C)(C)C | 2927.0 | Semi standard non polar | 33892256 | | Prostaglandin A1,2TMS,isomer #3 | CCCCC[C@H](O)/C=C/[C@H]1C=CC(O[Si](C)(C)C)=C1CCCCCCC(=O)O[Si](C)(C)C | 2841.4 | Semi standard non polar | 33892256 | | Prostaglandin A1,3TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1C=CC(O[Si](C)(C)C)=C1CCCCCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 2941.2 | Semi standard non polar | 33892256 | | Prostaglandin A1,3TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1C=CC(O[Si](C)(C)C)=C1CCCCCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 2755.6 | Standard non polar | 33892256 | | Prostaglandin A1,3TMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1C=CC(O[Si](C)(C)C)=C1CCCCCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 3073.2 | Standard polar | 33892256 | | Prostaglandin A1,1TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1C=CC(=O)[C@@H]1CCCCCCC(=O)O)O[Si](C)(C)C(C)(C)C | 3050.1 | Semi standard non polar | 33892256 | | Prostaglandin A1,1TBDMS,isomer #2 | CCCCC[C@H](O)/C=C/[C@H]1C=CC(=O)[C@@H]1CCCCCCC(=O)O[Si](C)(C)C(C)(C)C | 2975.2 | Semi standard non polar | 33892256 | | Prostaglandin A1,1TBDMS,isomer #3 | CCCCC[C@H](O)/C=C/[C@H]1C=CC(O[Si](C)(C)C(C)(C)C)=C1CCCCCCC(=O)O | 3108.0 | Semi standard non polar | 33892256 | | Prostaglandin A1,2TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1C=CC(=O)[C@@H]1CCCCCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3316.6 | Semi standard non polar | 33892256 | | Prostaglandin A1,2TBDMS,isomer #2 | CCCCC[C@@H](/C=C/[C@H]1C=CC(O[Si](C)(C)C(C)(C)C)=C1CCCCCCC(=O)O)O[Si](C)(C)C(C)(C)C | 3395.4 | Semi standard non polar | 33892256 | | Prostaglandin A1,2TBDMS,isomer #3 | CCCCC[C@H](O)/C=C/[C@H]1C=CC(O[Si](C)(C)C(C)(C)C)=C1CCCCCCC(=O)O[Si](C)(C)C(C)(C)C | 3315.4 | Semi standard non polar | 33892256 | | Prostaglandin A1,3TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1C=CC(O[Si](C)(C)C(C)(C)C)=C1CCCCCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3642.2 | Semi standard non polar | 33892256 | | Prostaglandin A1,3TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1C=CC(O[Si](C)(C)C(C)(C)C)=C1CCCCCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3227.2 | Standard non polar | 33892256 | | Prostaglandin A1,3TBDMS,isomer #1 | CCCCC[C@@H](/C=C/[C@H]1C=CC(O[Si](C)(C)C(C)(C)C)=C1CCCCCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3267.8 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Prostaglandin A1 GC-MS (Non-derivatized) - 70eV, Positive | splash10-0673-4092000000-6874868660d1be2cc397 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Prostaglandin A1 GC-MS (2 TMS) - 70eV, Positive | splash10-0006-9103300000-0b8807822e2ae6a44c8e | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Prostaglandin A1 GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Prostaglandin A1 10V, Positive-QTOF | splash10-0gb9-0029000000-ef612f000f40cf5fb612 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Prostaglandin A1 20V, Positive-QTOF | splash10-0l6u-3194000000-1d504119f0ddf6f99cfc | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Prostaglandin A1 40V, Positive-QTOF | splash10-05tv-9120000000-04e28ba462f08d52e16b | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Prostaglandin A1 10V, Negative-QTOF | splash10-000i-0019000000-af954838d61275b1a6b2 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Prostaglandin A1 20V, Negative-QTOF | splash10-014r-2159000000-3d6b28690c12cfabfbb1 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Prostaglandin A1 40V, Negative-QTOF | splash10-0a4i-9540000000-0657404cf2ca8a295d26 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Prostaglandin A1 10V, Positive-QTOF | splash10-0uxr-0019000000-943865bd4f76ac81c5b5 | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Prostaglandin A1 20V, Positive-QTOF | splash10-0uxr-8978000000-1b9129ec137ac84e784f | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Prostaglandin A1 40V, Positive-QTOF | splash10-05qc-9500000000-74f6b19254976131ff01 | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Prostaglandin A1 10V, Negative-QTOF | splash10-014r-0029000000-eee5cd4fa1c96d9b3408 | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Prostaglandin A1 20V, Negative-QTOF | splash10-00kr-0597000000-eae1be9c15781533cefc | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Prostaglandin A1 40V, Negative-QTOF | splash10-05oa-5940000000-1dadced25493924491cc | 2021-09-24 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Sasaki H, Fukushima M: Prostaglandins in the treatment of cancer. Anticancer Drugs. 1994 Apr;5(2):131-8. [PubMed:8049495 ]
- Gueriguian FL: Prostaglandin-macromolecule interactions. I. Noncovalent binding of prostaglandins A1, E1, F2alpha, and E2 by human and bovine serum albumins. J Pharmacol Exp Ther. 1976 May;197(2):391-401. [PubMed:944773 ]
- Montgomery RG, Patel NC, Lee JG: A comparison of the diuretic effects of prostaglandin A1, sodium ethacrynate, and placebo. Int J Clin Pharmacol Biopharm. 1975 Jul;12(1-2):102-8. [PubMed:1165130 ]
- Aitokallio-Tallberg A, Viinikka L, Ylikorkala O: Urinary 6-keto-prostaglandin F1a in patients with gynaecological tumours. Cancer Lett. 1987 Feb;34(2):201-6. [PubMed:3545443 ]
- Zhu Y, Gu ZL, Liang ZQ, Zhang HL, Qin ZH: Prostaglandin A1 inhibits increases in intracellular calcium concentration, TXA(2) production and platelet activation. Acta Pharmacol Sin. 2006 May;27(5):549-54. [PubMed:16626509 ]
- Santoro MG: Heat shock proteins and virus replication: hsp70s as mediators of the antiviral effects of prostaglandins. Experientia. 1994 Nov 30;50(11-12):1039-47. [PubMed:7988663 ]
- Fukushima S, Kishimoto S, Takeuchi Y, Fukushima M: Preparation and evaluation of o/w type emulsions containing antitumor prostaglandin. Adv Drug Deliv Rev. 2000 Dec 6;45(1):65-75. [PubMed:11104898 ]
|
|---|